Staff

Lead researchers

Professor Peter Johnson CBE MD FRCP FMedSci

Professor of Medical Oncology
Connect with Peter

Email: [email protected]

Other researchers

Professor Diana Eccles

Dean of Medicine

Research interests

  • Genetic predispostion to cancer
  • Cancer susceptibility variant interpetation and clinical application
  • Patient communication to optimise shared decision making
Connect with Diana

Email: [email protected]

Professor Tim Underwood

Professor of Gastrointestinal Surgery
Connect with Tim

Email: [email protected]

Professor Stephen Beers

Professor of Immunology & Immunotherapy
Connect with Stephen

Email: [email protected]

Professor Jon Strefford PhD

Head of School
Connect with Jon

Email: [email protected]

Dr Jeremy Blaydes

Associate Professor

Research interests

  • Transcriptional responses to pathways: roles in the causes and treatment of cancer Intra-cellular stress-response pathways are activated in response to potentially deleterious conditions in the cell’s environment. In single celled organisms these pathways are generally involved in ensuring the survival and replication of the individual cell. In complex multi-cellular organisms such as man, they are critical in maintaining the normal function of each organ in the body, and the survival of the organism as a whole. Stress-response pathways play a key role in the patho-physiology and treatment of many diseases, including cancer.At almost every stage of the development of a tumour, cells are exposed to some form of stress. Examples include exposure to toxic compounds or radiation, loss of contact with other cells or the extra-cellular matrix, lack of oxygen (hypoxia), acidic pH, the activation of oncogenes, induction of cellular senescence, oxidative damage or depletion of essential metabolites. In some circumstances, the activation of a stress-response pathway will actually help the tumour cell to survive and proliferate. In other situations the response is cell cycle arrest or programmed cell death (apoptosis), providing a barrier to further tumour development that the tumour may ultimately circumvent through the acquisition of a mutation in one of the genes within the stress-response pathway. The p53 tumour suppressor protein is a key component of one such stress-response pathway, and virtually all cancers loose functionality of the p53-stress response pathway. Many current and prospective treatments for cancer work by either inhibiting, or re-activating stress response pathways.Our work focuses on the role of regulators of gene transcription in the response of cancer cells to stress. We have a long-standing interest in the p53 protein, a stress-activated transcriptional activator. We have also developed interests in other pathways which regulate gene transcription and cancer cell proliferation in response to stress and changes in cell metabolism. We aim to determine the role of these pathways in the development of cancer, and establish the potential for targeting components of the pathways for cancer therapy.Our group is based in the purpose-built Somers Cancer Research Building. Modern, well equipped laboratories provide us with an excellent research environment, and the opportunity to interact with researchers working on related areas of cancer biology.
  • Some Example Projects: Regulation of HDM2 and HDMX proteins The HDM2 oncoprotein is the major negative regulator of p53 function in the cell. In the late 1990s work from a number of groups, including Blaydes et al , demonstrated that HDM2 could be targeted in cancer cells to re-activate the p53 stress-response pathway. Subsequently, small molecule inhibitors of HDM2 have been developed that show great promise in pre-clinical trials. We have undertaken a series of projects examining how HDM2, and its paralogue HDMX is regulated in cancer cells (see Phillips et al, 2010, 2008, 2007, 2006a, 2006b and Phelps et al 2005, 2003). A particular interest of our work has been how HDM2 and HDMX protein synthesis is controlled in response to cell-signalling pathways in different cell types, and how this affects p53 function in these cells.
  • Role of CtBP transcriptional repressors in cancer cell proliferation and survival In common with p53, CtBP1 and CtBP2 proteins were discovered through their physical association with a viral oncoprotein. We have shown that CtBPs also interact with HDM2 protein, and can consequently regulate p53 function (Mirnezami et al, 2003). The main function of CtBPs is as transcriptional co-repressors. They are involved in a range of cellular processes, depending upon the transcriptional repressor that recruits them to DNA, and they suppress the transcription of genes that cause apoptosis (reviewed in Bergman et al, 2006a). CtBP activity is modified by UV radiation and glycolytic metabolism, suggesting that CtBPs regulate cell survival in response to cellular stress. From 2004 The Breast Cancer Campaign has funded work in our laboratory to study the role of CtBPs in breast cancer. Our studies have progressed from studies of the basic mechanisms whereby CtBPs control breast cancer proliferation and survival (Birts et al 2011 and Bergman et al 2009, 2006a) to their impact on the response to current chemotherapies (Birts et al 2010) to the demonstration that CtBPs are themselves a therapeutically tractable potential molecular target for cancer therapy (Birts et al 2013). Our group was named Breast Cancer Campaign “Team of the Year 2011” on the basis of this work.
Connect with Jeremy

Email: [email protected]

Professor Edd James

Associate Dean Infrastructure

Research interests

  • Antigen processing and presentation
  • Regulation of T cell responses in anti-tumour responses
Connect with Edd

Email: [email protected]

Professor John Primrose

Professor of Surgery

Research interests

  • Professor Primrose’s research is in gastrointestinal cancer, clinical and translational and Health Services Research. The focus is on improving outcomes for patients undergoing surgical treatment for cancer. This is being achieved through devising and undertaking large scale national and international trials. All the studies are associated with tissue collections with a view to the development of biomarkers which will have prognostic value and may also predict response to therapy.
Connect with John

Email: [email protected]

Professor Ramsey Cutress

Professor of Breast Surgery
Connect with Ramsey

Email: [email protected]

Professor Francesco Forconi

Professor of Haematology
Connect with Francesco

Email: [email protected]

Professor Alex Mirnezami

Professor of Surgical Oncology
Connect with Alex

Email: [email protected]

Professor Mark Cragg

Professor in Experimental Cancer Biology

Research interests

  • Antibody biology
  • Antibody engineering
  • Cancer Immunotherapy
Connect with Mark

Email: [email protected]

Professor Aymen Al-Shamkhani

Professor in Immunology

Research interests

  • Cancer Immunotherapy
  • Immunobiology of costimulatory receptors
  • Immunostimulatory antibodies
Connect with Aymen

Email: [email protected]

Professor Simon Crabb PhD, BSc, MBBS, MRCP

Professor of Exp'tl Cancer Therapeutics

Research interests

  • Bladder cancer
  • Prostate cancer
  • Predictive biomarkers
Connect with Simon

Email: [email protected]

Emeritus Professor Graham Packham

Connect with Graham

Email: [email protected]

Professor Juliet Gray

Professor

Research interests

  • Fc modification of monoclonal antibodies to improve effector function
Connect with Juliet

Email: [email protected]

Dr Ellen Copson MB BS, PhD, FRCP

Professor
Connect with Ellen

Email: [email protected]

Professor Gareth Thomas

Professor of Experimental Pathology

Research interests

  • Fibroblast biology and immunology
  • Tumour microenvironment
  • Cancer Immunotherapy
Connect with Gareth

Email: [email protected]

Professor Sean Lim

Professor of Haematology

Research interests

  • Identification of new therapeutic targets in lymphoma
  • Development of novel monoclonal antibody combination therapies for cancer
  • Understanding the determinants of an effective immune response in patients with lymphoma
Connect with Sean

Email: [email protected]

Research outputs

The hydropathy index of the HCDR3 region of the B-Cell receptor identifies two subgroups of IGHV-mutated chronic lymphocytic leukemia patients with distinct outcome
Arancha Rodríguez-Caballero, Blanca Fuentes Herrero, Guillermo Oliva Ariza, Ignacio Criado, Miguel Alcoceba, Carlos Prieto, María Pérez Caro, Andrés C García-Montero, Marcos González Díaz, Francesco Forconi, Ana Bela Sarmento-Ribeiro, Julia Almeida & Alberto Orfao, 2021, Frontiers in Oncology, 11
DOI: 10.3389/fonc.2021.723722
Type: article
The predictive ability of the 313 variant–based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant
Inge M.M. Lakeman, Alexandra J. van den Broek, Juliën A.M. Vos, Daniel R. Barnes, Julian Adlard, Irene L. Andrulis, et al., Adalgeir Arason, Norbert Arnold, Banu K. Arun, Judith Balmaña, Daniel Barrowdale, Javier Benitez, Ake Borg, Trinidad Caldés, Maria A. Caligo, Wendy K. Chung, Kathleen B.M. Claes, Emmanuelle Barouk-Simonet, Muriel Belotti, Pascaline Berthet, Yves Jean Bignon, Valérie Bonadona, Brigitte Bressac-de Paillerets, Bruno Buecher, Sandrine Caputo, Olivier Caron, Laurent Castera, Virginie Caux-Moncoutier, Chrystelle Colas, Marie Agnès Collonge-Rame, Isabelle Coupier, Antoine de Pauw, Capucine Delnatte, Camille Elan, Laurence Faivre, Sandra Fert Ferrer, Marion Gauthier-Villars, Paul Gesta, Sophie Giraud, Lisa Golmard, Claude Houdayer, Christine Lasset, Maïté Laurent, Dominique Leroux, Michel Longy, Véronique Mari, Sylvie Mazoyer, Noura Mebirouk, Lucy E. Side & Diana M. Eccles, 2021, Genetics in Medicine, 23(9), 1726-1737
DOI: 10.1038/s41436-021-01198-7
Type: article